Published on July 10, 2025 by Alexis Behra
Sector Summary: Antibodies & Recombinant Proteins
In 2025, France BioLead brought together more than a hundred academic and industry experts to identify high-value R&D priorities, technological bottlenecks, and key French capabilities.
Co-organized with the Bioproduction & Biotherapies Integrator Network (RIBB) and the PEPR Biotherapies program, these meetings were structured by biomedicine family.
This summary focuses on antibodies & recombinant proteins. It describes the technological bottlenecks related to therapy types and manufacturing processes, analyzes priority R&D areas, and maps out the French expertise and resources.
These summaries will be updated periodically, and we would be happy to receive your feedback.
